Please assess the completion status of the following clinical trial:

Trial Title: Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed histologically proven locoregional oral squamous cell carcinoma (OSCC) without evidence of distant metastases. OSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone and buccal mucosa OR~Recurrent or persistent histologically proven locoregional OSCC that was initially treated with surgery alone.~* must be eligible for surgical resection~* greater than 18 years of age~Exclusion Criteria:~* prior immunotherapy or treatment with another anti PD-1 agent besides nivolumab~* prior chemotherapy including cetuximab or radiation therapy~* concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma~* unresectable primary tumor or regional disease or distant metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Received Nivolumab (Type: None): None
- Nivolumab Naive (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).